Loading
A phase 3 trial testing LM-108 in gastric & gastro-oesophageal junction cancer, now recruiting.
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma is a phase 3 interventional study registered as NCT07362186, led by LaNova Medicines, and recruiting on the registry. Official title: A Phase III, Open-Label, Multicenter, Randomised, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Planned enrolment is 400 participants (estimated). The study started in 2026-04-30 and primary completion is expected in 2028-08-17. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/